Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Contingency Plan for Power or Equipment Failure – V 2.0

Posted on By

BA-BE Studies: SOP for Contingency Plan for Power or Equipment Failure – V 2.0

Standard Operating Procedure for Contingency Plan for Power or Equipment Failure in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/102/2025
Supersedes SOP/BA-BE/102/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a contingency plan for managing power outages or equipment malfunctions during the clinical phase of BA/BE studies, thereby ensuring subject safety, sample integrity, and uninterrupted data collection.

2. Scope

This SOP applies to all clinical personnel, facility managers, and technical teams involved in operating, monitoring, and maintaining equipment or systems supporting the clinical phase of BA/BE studies.

3. Responsibilities

  • Facility Engineer: Ensures power backup systems and emergency equipment are in functional condition.
  • QA Officer: Verifies and audits contingency preparedness documentation and implementation.
  • Study Nurse / CRC: Monitors subject safety during interruptions and documents all actions taken.
  • Principal Investigator (PI): Oversees subject protection and study continuation decisions during failures.
See also  BA-BE Studies: SOP for Laboratory Safety Tests Prior to Dosing - V 2.0

4. Accountability

The Head of Clinical Operations is accountable for ensuring that the contingency procedures are in place, tested periodically, and followed strictly during actual events.

5. Procedure

5.1 Preventive Measures

  1. All critical equipment (freezers, centrifuges, ECG, dosing area lights, data systems) must be connected to UPS or diesel generator backup.
  2. Backup power systems to be tested monthly (see Annexure-1: Power Backup Test Log).
  3. Spare equipment (e.g., manual stopwatch, backup centrifuge) should be available.

5.2 Identification of Power or Equipment Failure

  1. In case of failure, the person identifying it must:
    • Immediately notify Facility Engineer
    • Inform PI and QA
    • Document the time and nature of failure (Annexure-2)

5.3 Clinical Continuity Protocol

  1. If dosing or sample collection is ongoing:
    • Switch to manual methods where possible (e.g., stopwatch, manual labels)
    • Ensure subject safety—relocate to ventilated or cooler area if required
  2. Document fallback procedures used in Annexure-3: Clinical Continuity Log.
See also  BA-BE Studies: SOP for Chain of Custody for Clinical Samples - V 2.0

5.4 Sample and Equipment Integrity

  1. Verify temperature logs of sample storage devices.
  2. Transfer samples to alternative freezers if backup fails.
  3. QA to assess and log impact of equipment failure on sample/data integrity (Annexure-4).

5.5 Restoration and Follow-Up

  1. Record restoration time and activities in Annexure-5: Incident Resolution Record.
  2. Initiate CAPA in case of critical deviations or non-recoverable data/sample loss.
  3. Inform sponsor and document in Deviation/Incident Report.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CRC: Clinical Research Coordinator
  • QA: Quality Assurance
  • PI: Principal Investigator
  • UPS: Uninterruptible Power Supply
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Power Backup Test Log – Annexure-1
  2. Equipment/Power Failure Notification Form – Annexure-2
  3. Clinical Continuity Log – Annexure-3
  4. QA Impact Assessment Log – Annexure-4
  5. Incident Resolution Record – Annexure-5

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • Indian GCP Guidelines

9. SOP Version

Version: 2.0

See also  BA-BE Studies: SOP for Preparing Product-Specific Guidance Review Summary - V 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Power Backup Test Log

Date System Tested Duration Tested By Status
10/04/2025 Generator 30 min Ravi Nair Pass

Annexure-2: Equipment/Power Failure Notification

Date/Time Nature of Failure Identified By Immediate Action
17/04/2025, 07:15 AM Freezer power loss Sunita Reddy Switched to UPS

Annexure-3: Clinical Continuity Log

Subject ID Activity Backup Action Time Logged Observer
VOL-102 Blood Draw Manual stopwatch used 07:20 AM CRC

Annexure-4: QA Impact Assessment Log

Date Impact Area Assessment Summary Action Required QA Reviewer
17/04/2025 Sample Stability No thawing observed None QA Officer

Annexure-5: Incident Resolution Record

Date/Time Restoration Action Resolved By Verified By
17/04/2025, 08:00 AM Power Restored Facility Engineer QA Officer

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial SOP System Implementation QA Head
17/04/2025 2.0 Annexures added and aligned to risk management plan Audit Compliance QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Elixir Department: SOP for Dispensing Under Laminar Airflow Cabinet – V 2.0
Next Post: Analytical Method Development: Technology Transfer of Analytical Methods – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version